RHY 2.15% 9.5¢ rhythm biosciences limited

Ann: AGM Presentation, page-8

  1. 194 Posts.
    lightbulb Created with Sketch. 37

    Looks like the international competition is hotting up folks. So it’s likely Colostat won’t be the first, second or even third blood test globally to be used as an early screening tool for colorectal cancer. Several are expected to be released in various parts of the world in 2019. Is this what’s dragging our SP down? At the end of the day I guess it’s a big world with a lot of arses, and the quality, ease and price of the test will be big drivers for who dominates. Roll on reagent development and clinical trials ASAP! 

    https://www.genengnews.com/topics/omics/swiss-viollier-to-launch-colorectal-cancer-blood-test-in-europe/

    https://www.japantimes.co.jp/news/2018/11/24/business/corporate-business/japans-shimadzu-corp-commercialize-new-blood-test-detect-early-stage-colon-cancer/#.XAUUqIp_WhA

 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
(20min delay)
Last
9.5¢
Change
0.002(2.15%)
Mkt cap ! $23.36M
Open High Low Value Volume
9.4¢ 9.5¢ 9.3¢ $7.655K 81.00K

Buyers (Bids)

No. Vol. Price($)
1 23132 9.4¢
 

Sellers (Offers)

Price($) Vol. No.
9.5¢ 171097 2
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
9.5¢
  Change
0.002 ( 2.15 %)
Open High Low Volume
9.4¢ 9.5¢ 9.3¢ 45575
Last updated 14.24pm 28/03/2024 ?
RHY (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.